Shares of J C Penney Company Inc (NYSE:JCP), declined -4.29% to $9.37, during its last trading session. In the last trading session, the stock moved on high volume, trading at a volume of 22.30 M as compared to its average daily volume of 11.84 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 0.97% which was maintained at -6.01% in 1-month period.
J C Penney Company stock declined after Citigroup initiated coverage on the stock with a ‘sell’ rating.
The firm set a price target of $7 on the stock.
J.C. Penney’s administration faces the difficult task of rebounding from a failed strategy with insufficient cash flow, and any improvement the company does see in operating cash flow will be negated by improvements in capital expenditures, Citigroup analysts said in a note, Barron’s reports.
J. C. Penney Company, Inc., through its partner, J. C. Penney Corporation, Inc., sells merchandise through department stores in the United States. The company sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products, and home furnishings, in addition to provides various services, counting styling salon, optical, portrait photography, and custom decorating. As of March 18, 2015, it operated about 1,060 stores.
On Wednesday, Shares of EXACT Sciences Corporation (NASDAQ:EXAS), gained 0.40% to $10.02. The stock attained the volume of 11.20 million shares.
The year-to-date (YTD) performance reflected a -63.48% below last year. During the past month the stock loses -52.35%, bringing three-month performance to -63.34% and six-month performance to -56.17%. The stock holds the market capitalization of 962.82M.
EXACT Sciences Corporation, issued the following statement recently following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.
USPSTF comprised Cologuard in the draft guidelines as an alternative screening test, together with CT colonography. The draft guidelines recommend an “A” rating for colorectal cancer screening starting at age 50 and ongoing until age 75. Screening for individuals age 75 through 85 is graded a “C.” This approach represents a change from the 2008 recommendations, which assigned specific grades for different tests, counting an “I” rating for stool-based DNA.
Cologuard is a non-invasive, FDA-approved colorectal cancer screening test that is covered by Medicare. Cologuard specifically and sDNA generally are comprised in the American Cancer Society and the U.S. Multi-Society Task Force screening guidelines, which comprise the American Gastroenterological Association, American College of Gastroenterolgy and American Society for Gastrointestinal Endoscopy.
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.
Shares of National-Oilwell Varco, Inc. (NYSE:NOV), declined -0.57% to $40.46, during its last trading session. In the last trading session, the stock moved on high volume, trading at a volume of 7.95 M as compared to its average daily volume of 6.36 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 7.49% which was maintained at 0.77% in 1-month period.
Credit Suisse maintains its rating on National Oilwell Varco, Inc. (NYSE:NOV). The global brokerage major lowers the current price target from $39 per share to $33 per share. Analysts at the Credit Suisse have a current rating of Underperform on the shares. The rating by the firm was issued on September 4, 2015.
National Oilwell Varco, Inc. designs, manufactures, and sells equipment and components used in oil and gas drilling, completion, and production; and provides oilfield services to the upstream oil and gas industry worldwide. The company’s Rig Systems segment offers land rigs; offshore drilling equipment packages; and drilling rig components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
